cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eagle Pharmaceuticals Inc
5 own
14 watching
Current Price
$5.72
$-0.02
(-0.35%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
176.27M
52-Week High
52-Week High
23.52000
52-Week Low
52-Week Low
3.21000
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
37.5328
iconMarket Capitalization176.27M
icon52-Week High23.52000
icon52-Week Low3.21000
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio37.5328
What does the Eagle Pharmaceuticals Inc do?
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Read More
How much money does Eagle Pharmaceuticals Inc make?
News & Events about Eagle Pharmaceuticals Inc.
Globe Newswire
1 year ago
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.Scott Tarriff, President...
Globe Newswire
1 year ago
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delawares decision that Eagles vasopressin product ...
Ticker Report
2years ago
BNP Paribas Arbitrage SA lessened its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 45.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 6,397 shares of the specialty pharmaceutical companys stock after selling 5,396 ...
Ticker Report
2years ago
Principal Financial Group Inc. decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,897 shares of the specialty pharmaceutical company&#...
Ticker Report
2years ago
Equities analysts forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) will report earnings per share of $3.91 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals earnings, with estimates ...
Frequently Asked Questions
Frequently Asked Questions
What is Eagle Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Eagle Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Eagle Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Eagle Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eagle Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Eagle Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Eagle Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eagle Pharmaceuticals Inc?
plus_minus_icon
What percentage is Eagle Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eagle Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.72
$-0.02
(-0.35%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.38
$0.08 (6.15 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$2.42
$-0.01 (-0.21 %)
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
$3.04
$-0.06 (-1.77 %)
Akebia Therapeutics Inc
Akebia Therapeutics Inc
$1.44
$-0.04 (-2.70 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$1.38
$0.08 (6.15 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$2.42
$-0.01 (-0.21 %)
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
$3.04
$-0.06 (-1.77 %)
Akebia Therapeutics Inc
Akebia Therapeutics Inc
$1.44
$-0.04 (-2.70 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00